Study title: A phase III, open, randomized, controlled study to evaluate the immunogenicity and safety of one dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children of 4 to 6 years of age previously primed with one dose of measles-mumps-rubella vaccine (GlaxoSmithKline Biologicals’ PriorixÔ or Merck & Co.’s M-M-R IIÔ)
| Type of medicine: Non-centrally authorised vaccines | |||||
| Therapeutic area: Virus Diseases | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: Live attenuated measles, mumps, rubella, varicella vaccine | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: 2011-11-22 | |||||
| Study number: 208136/019 (MeMuRu-OKA-019) | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |